Clinical Trials Logo

Osteosarcoma Recurrent clinical trials

View clinical trials related to Osteosarcoma Recurrent.

Filter by:
  • None
  • Page 1

NCT ID: NCT04803877 Active, not recruiting - Osteosarcoma Clinical Trials

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

Start date: June 4, 2021
Phase: Phase 2
Study type: Interventional

A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.

NCT ID: NCT04651569 Completed - Clinical trials for Osteosarcoma Recurrent

An Analysis of the Efficacy of High Dose Isofosfamide Through Elastomer

Start date: October 2, 2020
Phase:
Study type: Observational

A multicentre, observational, retrospective study to analyse the efficacy of high dose isofosfamide thorugh elastomer in patients with relapsed/ refractory osteosarcoma

NCT ID: NCT04651179 Completed - Clinical trials for Osteosarcoma Recurrent

Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma

Start date: April 24, 2020
Phase:
Study type: Observational

A retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment

NCT ID: NCT04417062 Recruiting - Osteosarcoma Clinical Trials

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Start date: November 24, 2020
Phase: Phase 2
Study type: Interventional

This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: - Olaparib - Ceralasertib

NCT ID: NCT03628209 Active, not recruiting - Sarcoma Clinical Trials

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Start date: October 3, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of nivolumab, or nivolumab in combination with azacitidine in participants with recurrent, resectable osteosarcoma